...
机译:表皮生长因子受体中S492R突变的频率:用Panitumumab或西妥昔单抗治疗转移结直肠癌患者的血浆DNA分析
Queen Elizabeth Hosp Clin Oncol Res Dept Woodville SA Australia;
Amgen Inc Clin Biomarkers Thousand Oaks CA USA;
Amgen Inc Clin Biomarkers Thousand Oaks CA USA;
Univ Ulsan Asan Med Ctr Dept Oncol Coll Med Seoul South Korea;
Tongji Univ Dept Oncol East Hosp Shanghai Peoples R China;
Univ Politecn Marche Dept Med Oncol Ancona Italy;
Univ Witwatersrand Fac Hlth Sci Johannesburg South Africa;
Apollo Hosp Dept Med Oncol Hyderabad India;
Univ Leicester Dept Oncol Leicester Leics England;
NN Blokhin Canc Res Ctr Rams Dept Clin Pharmacol &
Chemotherapy Moscow Russia;
Antwerp Univ Hosp Dept Oncol Edegem Belgium;
Colorectal cancer; gene mutations; resistance; cetuximab; panitumumab; anti-epidermal growth factor receptor;
机译:3019 POSTER帕尼单抗单药治疗的转移性结直肠癌(mCRC)患者的表皮生长因子受体(EGFr)基因拷贝数(GCN)与临床结局的关联
机译:I阶段研究抗肝素结合的表皮生长因子样生长因子抗体U3-1565与西妥昔单抗或胰岛素抗性转移结直肠癌患者
机译:活化KRAS突变和表皮生长因子受体的过表达作为西妥昔单抗治疗转移性结直肠癌患者的独立预测因子。
机译:西妥昔单抗缀合的近红外硫化银量子点靶向表皮生长因子受体(EGFR)阳性胰腺癌细胞系
机译:与人表皮生长因子受体阳性(HER2 +)转移性乳腺癌相关的间接成本
机译:表皮生长因子受体S492R突变的频率:用Panitumumab或西妥昔单抗治疗转移结直肠癌患者的血浆DNA分析
机译:表皮生长因子受体S492R突变的频率:用Panitumumab或西妥昔单抗治疗转移结直肠癌患者的血浆DNA分析
机译:乳腺癌:表皮生长因子受体,mDm2和p53突变的参与